en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
2/2014
vol. 52
 
Share:
Share:
more
 
 
abstract:
Review paper

Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs

Anna Filipowicz-Sosnowska
,
Piotr Głuszko
,
Robert Rupiński

Reumatologia 2014; 52, 2: 120–128
Online publish date: 2014/06/04
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Cardiovascular events are the main cause of the increased risk of death in patients with rheumatoid arthritis (RA). Death rates associated with cardiovascular diseases in RA are 50% higher in comparison with the general population. In the last decade several new technologies and new strategy in the treatment of RA were introduced but the risk of cardiovascular incidents remained unchanged. Various alterations of the lipid profile, observed in RA patients during the treatment with disease modifying antirheumatic drugs (DMARDs) are the subject of several and often contraversal studies. In this review we present and analyzed the results of current research on the lipid profile in RA patients treated with the synthetic and biologic DMARDs. The role of the lipid profile alterations in the pathogenesis of accelerated atherosclerosis in RA has been discussed.
keywords:

rheumatoid arthritis, lipid profiles, dislipidemia, disease-modifying antirheumatic drugs







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.